Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by widespread immune dysregulation and systemic inflammation. This disorder can affect many organs of the body, such as the skin, joints, kidneys, nervous system, and cardiovascular system.

Although tissue biopsies provide insight into organ-specific pathology, Systemic lupus erythematosus Samples, particularly serum and plasma, provide a minimally invasive yet highly informative window into systemic immune activity.

At Bay Biosciences, we provide high-quality Systemic lupus erythematosus Samples for research, including well-characterized human serum and plasma and PBMC biofluids that allow researchers to study autoantibodies, cytokines, complement proteins, and immune signaling pathways associated with disease onset and progression.

Systemic Lupus Erythematosus Research

Understanding Systemic Lupus Erythematosus

Systemic lupus erythematosus is a complex autoimmune disease in which the immune system produces antibodies against the body’s own cellular components.

These autoantibodies target nuclear antigens such as DNA, histones, and ribonucleoproteins.

When these antibodies bind to their targets, they form immune complexes that circulate in the bloodstream and deposit in tissues. This immune complex deposition triggers inflammation and tissue damage in multiple organs.

The systemic lupus erythematosus disorder is driven by dysregulated interactions between B cells, T cells, dendritic cells, and other components of the immune system. B cells produce pathogenic autoantibodies, while T helper cells promote their activation and persistence.

In addition, cytokines such as interferons and other inflammatory mediators contribute to immune activation and chronic inflammation.

Because these immune processes occur throughout the body, circulating biomarkers present in blood provide valuable insights into disease biology.

As a result, Systemic lupus erythematosus Samples, particularly serum and plasma, play an essential role in advancing research on immune dysfunction and therapeutic targets.

Causes Of Systemic Lupus Erythematosus

Research suggests that SLE arises from a combination of genetic susceptibility, environmental triggers, and other factors.

Firstly, genetic factors significantly increase disease risk. Variants in genes involved in immune regulation, complement pathways, and interferon signaling increase susceptibility to systemic lupus erythematosus.

Secondly, environmental triggers also contribute to disease onset in genetically predisposed individuals.

These triggers include:

However, research shows that SLE often develops when environmental triggers, such as infectious agents, activate the immune system in genetically susceptible individuals.

Therefore, although a genetic component is present, environmental triggers drive disease development.

Common Symptoms of Systemic Lupus Erythematosus

Symptoms of systemic lupus erythematosus vary widely because the disease can affect multiple organs and tissues.

Common symptoms include:

Many patients also experience periods of worsening symptoms followed by intervals of relative remission.

Because systemic inflammation affects multiple organ systems, researchers rely on

Systemic lupus erythematosus Samples to investigate immune markers associated with disease activity and progression.

Systemic Lupus Erythematosus with Nephritis

One of the most serious complications of SLE is kidney involvement, known as systemic lupus erythematosus with nephritis or lupus nephritis.

In lupus nephritis, the immune system produces autoantibodies that react with components of the body’s own cells. These antibodies combine with antigens and form immune complexes in the bloodstream. The immune complexes then deposit in the glomeruli of the kidneys.

After these immune complexes settle in the glomeruli, they activate the complement system and attract inflammatory cells. This immune response causes inflammation and damages the kidney’s filtering structures.

As the damage increases, the kidneys lose their ability to filter waste and excess fluid efficiently.

Monitoring circulating biomarkers through SLE Serum Samples allows researchers to identify immune signatures associated with kidney involvement and disease severity.

Diagnosis of Systemic Lupus Erythematosus

Diagnosing systemic lupus erythematosus requires a combination of clinical evaluation, laboratory testing, and immunological assays.

Common diagnostic tests include:

  • Antinuclear antibody (ANA) testing
  • Anti-double-stranded DNA (anti-dsDNA) antibodies
  • Anti-Smith antibodies
  • Complement protein levels (C3 and C4)
  • Complete blood count (CBC)
  • Urinalysis for kidney involvement

These laboratory findings help clinicians identify disease activity and organ involvement.

The disease is also classified using international diagnostic criteria and medical coding systems, including systemic lupus erythematosus ICD 9 classifications, which historically helped standardize diagnosis and clinical documentation.

Systemic Lupus Erythematosus Therapy

Modern systemic lupus erythematosus therapy aims to control inflammation, suppress abnormal immune responses, and prevent organ damage.

Treatment strategies vary depending on disease severity and affected organs.

Common therapeutic approaches include:

1. Nonsteroidal anti-inflammatory drugs (NSAIDs)

These medications help relieve joint pain and inflammation during mild disease activity.

2. Corticosteroids

In fact, corticosteroids such as prednisone are frequently used to suppress immune activation during acute disease flares.

3. Immunosuppressive medications

Drugs such as azathioprine, mycophenolate mofetil, and cyclophosphamide help reduce autoantibody production and control systemic inflammation.

4. Biologic therapies

Targeted biologic treatments such as belimumab inhibit B-cell activating factors and reduce autoantibody production.

5. Antimalarial drugs

Hydroxychloroquine is widely used in lupus management because it helps reduce disease flares and improve long-term outcomes.

Although these treatments have significantly improved survival rates, ongoing research is essential to identify more precise therapeutic targets.

High-quality SLE samples for research are therefore crucial for developing next-generation therapies and personalized treatment strategies.

Serum and Plasma in Systemic Lupus Erythematosus Research

Serum and plasma are two important blood-derived biospecimens used extensively in autoimmune disease research.

Both matrices contain numerous biologically active molecules, including:

  • Autoantibodies
  • Cytokines and chemokines
  • Complement proteins
  • Immune complexes
  • Metabolic biomarkers
  • Extracellular vesicles

One of the most important applications of SLE Serum Samples is the detection and quantification of autoantibodies such as anti-dsDNA and anti-Smith antibodies. These markers are widely used to evaluate disease activity and monitor treatment response.

Plasma samples also allow researchers to study complement system activation, cytokine signaling pathways, and inflammatory mediators involved in lupus pathogenesis.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we are committed to providing reliable Systemic lupus erythematosus Samples that support scientific investigations.

Our collection protocols prioritize rapid processing, strict quality control, and controlled storage conditions to preserve the biological integrity of each specimen.

We provide each sample with relevant clinical data, including diagnosis, disease stage, and treatment history, enabling researchers to conduct meaningful translational and biomarker studies.

Our wide range of biospecimens includes:

Samples from normal healthy donors, volunteers, for controls, and clinical research are also available.

If you have any questions, concerns, or special requests, please don’t hesitate to reach out to us!